R

R&G PharmaStudies Co Ltd
SZSE:301333

Watchlist Manager
R&G PharmaStudies Co Ltd
SZSE:301333
Watchlist
Price: 58.41 CNY -2.81% Market Closed
Market Cap: 5.6B CNY
Have any thoughts about
R&G PharmaStudies Co Ltd?
Write Note

R&G PharmaStudies Co Ltd
Total Receivables

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
|

R&G PharmaStudies Co Ltd
Total Receivables Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Total Receivables CAGR 3Y CAGR 5Y CAGR 10Y
R
R&G PharmaStudies Co Ltd
SZSE:301333
Total Receivables
ÂĄ246m
CAGR 3-Years
21%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
WuXi AppTec Co Ltd
SSE:603259
Total Receivables
ÂĄ10.1B
CAGR 3-Years
23%
CAGR 5-Years
29%
CAGR 10-Years
N/A
Pharmaron Beijing Co Ltd
SZSE:300759
Total Receivables
ÂĄ2.9B
CAGR 3-Years
23%
CAGR 5-Years
25%
CAGR 10-Years
N/A
WuXi Biologics (Cayman) Inc
HKEX:2269
Total Receivables
ÂĄ6.8B
CAGR 3-Years
13%
CAGR 5-Years
41%
CAGR 10-Years
N/A
Hangzhou Tigermed Consulting Co Ltd
SZSE:300347
Total Receivables
ÂĄ4.3B
CAGR 3-Years
31%
CAGR 5-Years
31%
CAGR 10-Years
33%
W
WuXi XDC Cayman Inc
HKEX:2268
Total Receivables
ÂĄ985.8m
CAGR 3-Years
177%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
No Stocks Found

R&G PharmaStudies Co Ltd
Glance View

Market Cap
5.6B CNY
Industry
Life Sciences Tools & Services

R&G PharmaStudies Co., Ltd. engages in the provision of clinical trial outsourcing services. The company is headquartered in Beijing, Beijing and currently employs 1,926 full-time employees. The company went IPO on 2022-08-02. The firm's main businesses include clinical trial operation services (CO Services), clinical trial site management services (SMO Services), biological sample testing services (BA Services), data management and statistical analysis services (DM/ST Services), clinical trials Consulting Services, Clinical Pharmacology Services (CP Services) and others. The firm operates its businesses primarily in the domestic market.

Intrinsic Value
57.24 CNY
Overvaluation 2%
Intrinsic Value
Price
R

See Also

What is R&G PharmaStudies Co Ltd's Total Receivables?
Total Receivables
246m CNY

Based on the financial report for Dec 31, 2023, R&G PharmaStudies Co Ltd's Total Receivables amounts to 246m CNY.

What is R&G PharmaStudies Co Ltd's Total Receivables growth rate?
Total Receivables CAGR 3Y
21%

Over the last year, the Total Receivables growth was 7%. The average annual Total Receivables growth rates for R&G PharmaStudies Co Ltd have been 21% over the past three years .

Back to Top